Article
Medicine, Research & Experimental
C. Le Gall-Ianotto, R. Verdet, E. Nowak, L. Le Roux, A. Gasse, A. Fiedler, D. Carlhant-Kowalski, P. Marcorelles, L. Misery, J. C. Ianotto
Summary: This study focuses on persistent aquagenic pruritus in MPN patients, comparing the effectiveness of two drugs to find new treatment options and gain further insights into the pathophysiology of the condition.
Article
Gastroenterology & Hepatology
Christopher L. Bowlus, Bertus Eksteen, Angela C. Cheung, Douglas Thorburn, Cynthia A. Moylan, Paul J. Pockros, Lisa M. Forman, Alejandro Dorenbaum, Gideon M. Hirschfield, Ciara Kennedy, Thomas Jaecklin, Andrew McKibben, Elaine Chien, Marshall Baek, Pamela Vig, Cynthia Levy
Summary: Maralixibat, an IBAT inhibitor, was found to lower bile acid levels and improve itching symptoms in patients with PSC. The adverse events during treatment were mainly gastrointestinal-related and mostly mild or moderate. These results support further investigation of IBAT inhibitors for the treatment of PSC-associated pruritus.
HEPATOLOGY COMMUNICATIONS
(2023)
Review
Endocrinology & Metabolism
Elvina Almuradova, Irfan Cicin
Summary: Cancer-related hypercalcemia is a common condition in advanced cancer patients and is seen in 20-30% of cases. The most frequent cause is malignancy. Hypercalcemia can occur in both solid tumor and hematologic malignancies and is associated with poor prognosis. Multiple mechanisms, such as abnormal calcium metabolism, can contribute to its development. Timely diagnosis and treatment by physicians can reduce complications and the main treatments include IV hydration, bisphosphonates, calcitonin, denosumab, prednisone, cinacalcet, and possible hemodialysis for severe refractory hypercalcemia in advanced kidney disease.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Pharmacology & Pharmacy
Majid Alam, Joerg Buddenkotte, Fareed Ahmad, Martin Steinhoff
Summary: Pruritus, or itch, is a common symptom in skin diseases and systemic disorders, with chronic pruritus causing distress and reduced quality of life. NK1R antagonists have shown significant anti-itch activity, suggesting they may be a therapeutic option for chronic pruritus in the future.
Article
Oncology
Eleni Papoui, Evridiki Papastavrou, Anastasios Merkouris, Andreas Charalambous
Summary: This study evaluated the effectiveness of an educational program for cancer patients experiencing pruritus, rash or photosensitivity caused by chemotherapy, EGFRI treatments, or immunotherapy. The program resulted in a significant improvement in the grades of skin reactions and higher functional health and wellbeing status for the intervention group. However, further validation over longer periods of time is needed.
EUROPEAN JOURNAL OF ONCOLOGY NURSING
(2022)
Article
Dermatology
Albert Baschong, Florian Spiess, Philippe C. Cattin, Alexander Navarini, Simon M. Mueller
Summary: The study demonstrates that visual exposure to antipruritic colors in immersive virtual reality can significantly reduce itch intensity, aligning with previous findings on the influence of colors on itch perception. The response to the intervention appears independent of psychometric values.
DERMATOLOGIC THERAPY
(2021)
Article
Oncology
Sakiko Kimura, Kazuhisa Hosoya, Kenji Ogata, Tatsuya Furuno, Rintaro Sogawa, Koji Takeuchi, Masanobu Tasaki, Atsushi Kawaguchi, Atsujiro Nishioka, Naoko Sueoka-Aragane, Hirokazu Noshiro, Yuichiro Kuratomi, Masatoshi Yokoyama, Mitsuru Noguchi, Keizo Anzai, Yoshio Yamashita, Shinya Kimura, Hiroyuki Irie
Summary: The study found that the incidence and severity of constipation significantly increased after treatment with palonosetron. Combination treatment with aprepitant and older age were associated with the severity of constipation.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
Debra Reis, Tisha Throne, Joan Keller, Christa Koffel, Tian Chen, Stacey Young-McCaughan
Summary: Patients with cancer are increasingly using essential oils to reduce the adverse effects of cancer treatment. This study aimed to determine if applying frankincense to the soles of the feet before, during, and after chemotherapy affects patients' perceptions of chemotherapy-related fatigue. However, no significant changes in fatigue were found.
Article
Physiology
Liuxi Chu, Xin Shu, Yan Wu, Haoran Yang, Qin Lu, Huihua Deng
Summary: This pilot study suggests that there may be abnormalities in peripheral blood levels of cortisol and cortisone, and the ratios of cortisone and testosterone to cortisol in patients with PN, which are related to pruritus severity. However, the plasma concentrations of testosterone and DHEA may be not abnormal in PN patients and may not be associated with pruritus severity.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Dermatology
Gil Yosipovitch, Ahmed Awad, Robert H. Spencer, Catherine Munera, Frederique Menzaghi
Summary: This study evaluated the efficacy and safety of difelikefalin in reducing itch in patients with non-dialysis-dependent chronic kidney disease and those undergoing hemodialysis. The results showed that difelikefalin significantly reduced itch intensity and improved itch-related quality of life in these patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Medicine, General & Internal
Hui-Qiong He, Wen-Tong Shen, Qin Pei, Jian-Biao Fei, Yue Yu, Hai-Hong Qin, Guo-Jiang Wang
Summary: This study evaluated the efficacy and safety of artemether emulsion on localized senile pruritus. The results showed that artemether emulsion was more effective in relieving pruritus compared to emulsion base, with no adverse events observed.
Article
Oncology
Stephanie Gu, Stephen Dusza, Elizabeth Quigley, Helen Haliasos, Alina Markova, Michael Marchetti, Andrea P. Moy, Chau Dang, Shanu Modi, Diana Lake, Sarah Noor, Mario E. Lacouture
Summary: This retrospective analysis examined the occurrence of pruritus in HER2 + breast cancer patients receiving trastuzumab and pertuzumab treatment. The results showed that pruritus was rare but could occur at different times after treatment initiation and mainly affected the upper extremities, back, lower extremities, and shoulders. Most cases of pruritus were grade 1/2, and patients responded well to treatment with topical steroids, antihistamines, emollients, and gabapentinoids. A small number of patients required treatment interruption or discontinuation.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Medicine, General & Internal
Emmanuel Gonzales, Winita Hardikar, Michael Stormon, Alastair Baker, Loreto Hierro, Dorota Gliwicz, Florence Lacaille, Alain Lachaux, Ekkehard Sturm, Kenneth D. R. Setchell, Ciara Kennedy, Alejandro Dorenbaum, Jana Steinmetz, Nirav K. Desai, Andrew J. Wardle, Will Garner, Pamela Vig, Thomas Jaecklin, Etienne M. Sokal, Emmanuel Jacquemin
Summary: Maralixibat showed safety and efficacy in children with Alagille syndrome, providing durable and clinically meaningful improvements in cholestasis. It may represent a new treatment paradigm for chronic cholestasis in Alagille syndrome.
Review
Oncology
Dan Cheng, Jing Wang, Zigang Dong, Xiang Li
Summary: Noncoding RNAs, including circRNAs, play an important role in various diseases, and their potential as biomarkers for cancer prognosis and diagnosis is discussed. The features, classification, and analysis methods of circRNAs are also summarized in this review.
CANCER CELL INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Jessica Lee, David Currow, Melanie Lovell, Jane L. Phillips, Andrew McLachlan, Megan Ritchie, Linda Brown, Belinda Fazekas, Rajesh Aggarwal, Davinia Seah, Caitlin Sheehan, Richard Chye, Beverly Noble, Nikki McCaffrey, Ghauri Aggarwal, Rachel George, Marian Kow, Chadi Ayoub, Anthony Linton, Christine Sanderson, Dipti Mittal, Angela Rao, Grace Prael, Katalin Urban, Priyanka Vandersman, Meera Agar
Summary: This study aims to evaluate the safety and efficacy of lidocaine as a treatment for neuropathic cancer-related pain in patients. The study will involve a pilot trial, pharmacokinetic substudy, and qualitative substudy. The findings will inform the design of further clinical trials and provide important safety data.
Article
Oncology
Maria Danieli, Francesco Barretta, Marco Fiore, Stefano Radaelli, Claudia Sangalli, Marta Barisella, Silvia Stacchiotti, Elena Palassini, Rosalba Miceli, Anna Maria Frezza, Dario Callegaro, Paolo Giovanni Casali, Alessandro Gronchi
Summary: The widespread use of preoperative treatments and increased availability of medical agents in recent years have been associated with improved outcomes for extremity and superficial trunk soft tissue sarcoma (ESTSTS) patients.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Editorial Material
Oncology
Maria Danieli, Francesco Barretta, Marco Fiore, Stefano Radaelli, Claudia Sangalli, Marta Barisella, Silvia Stacchiotti, Elena Palassini, Rosalba Miceli, Anna Maria Frezza, Dario Callegaro, Paolo Giovanni Casali, Alessandro Gronchi
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Giacomo G. Baldi, Salvatore Lo Vullo, Giovanni Grignani, Bruno Vincenzi, Giuseppe Badalamenti, Marinella Mastore, Ciriaco Buonomenna, Carlo Morosi, Marta Barisella, Anna Maria Frezza, Salvatore Provenzano, Noemi Simeone, Fernanda Picozzi, Luigi Mariani, Paolo G. Casali, Silvia Stacchiotti
Summary: This study retrospectively analyzed the efficacy and survival outcomes of weekly cisplatin (wCDDP) as a single agent or combined with imatinib (wCDDP/I) in patients with advanced chordoma. The results showed that both wCDDP and wCDDP/I had antitumor activity in chordoma, and a proportion of patients had no disease progression at 6 and 12 months. Further prospective studies are needed.
Review
Oncology
J. Y. Blay, N. Hindi, J. Bollard, S. Aguiar Jr, M. Angel, B. Araya, R. Badilla, D. Bernabeu, F. Campos, C. H. S. Caro-Sanchez, B. Carvajal, A. Carvajal Montoya, S. Casavilca-Zambrano, V Castro-Oliden, M. Chacon, M. Clara, P. Collini, R. Correa Genoroso, F. D. Costa, M. Cuellar, A. P. dei Tos, H. R. Dominguez Malagon, D. Donati, A. Dufresne, M. Eriksson, M. Farias-Loza, P. Fernandez, A. M. Frezza, T. Frisoni, D. Y. Garcia-Ortega, H. Gelderblom, F. Gouin, M. C. Gomez-Mateo, A. Gronchi, J. Haro, L. Huanca, N. Jimenez, M. Karanian, B. Kasper, B. B. Lopes David, A. Lopez-Pousa, G. Lutter, H. Martinez-Said, J. Martinez-Tlahuel, C. A. Mello, J. M. Morales Perez, S. Moura David, A. G. Nascimento, E. J. Ortiz-Cruz, E. Palmerini, S. Patel, Y. Pfluger, S. Provenzano, A. Righi, A. Rodriguez, R. Salas, T. T. G. Santos, K. Scotlandi, T. Soule, S. Stacchiotti, C. Valverde, F. Waisberg, E. Zamora Estrada, J. Martin-Broto
CANCER TREATMENT REVIEWS
(2022)
Review
Oncology
J. Y. Blay, E. Palmerini, J. Bollard, S. Aguiar Jr, M. Angel, B. Araya, R. Badilla, D. Bernabeu, F. Campos, C. H. S. Caro-Sanchez, A. Carvajal Montoya, S. Casavilca-Zambrano, V Castro-Oliden, M. Chacon, M. A. Clara-Altamirano, P. Collini, R. Correa Genoroso, F. D. Costa, M. Cuellar, A. P. dei Tos, H. R. Dominguez Malagon, D. M. Donati, A. Dufresne, M. Eriksson, M. Farias-Loza, A. M. Frezza, T. Frisoni, D. Y. Garcia-Ortega, H. Gerderblom, F. Gouin, M. C. Gomez-Mateo, A. Gronchi, J. Haro, N. Hindi, L. Huanca, N. Jimenez, M. Karanian, B. Kasper, A. Lopes, B. B. Lopes David, A. Lopez-Pousa, G. Lutter, R. G. Maki, H. Martinez-Said, J. L. Martinez-Tlahuel, C. A. Mello, J. M. Morales Perez, D. S. Moura, S. A. Nakagawa, A. G. Nascimento, E. J. Ortiz-Cruz, S. Patel, Y. Pfluger, S. Provenzano, A. Righi, A. Rodriguez, T. G. Santos, K. Scotlandi, M. L. G. Silva, T. Soule, S. Stacchiotti, C. M. Valverde, F. Waisberg, E. Zamora Estrada, J. Martin-Broto
Summary: Bone sarcoma is a rare disease with a low incidence in adult population. The multidisciplinary management and expert discussion of diagnostic and therapeutic strategies are essential for these patients. The Sarcoma European Latin-American Network (SELNET) aims to improve clinical outcomes in sarcoma care, with a specific focus on Latin-American countries. The Clinical Practice Guidelines (CPG) developed by SELNET provide a standardized approach to diagnose, treat, and follow-up bone sarcoma patients in the Latin-American context.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Aparna Subramaniam, Claudia Giani, Andrea Napolitano, Vinod Ravi, Anna Maria Frezza, Robin L. Jones
Summary: Vascular sarcomas are a group of soft tissue sarcomas with diverse clinical behaviors, biological features, and treatment approaches. Treatment in specialized centers or networks is crucial, and their diversity needs to be considered in clinical trial design.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
(2022)
Article
Oncology
Anna Maria Frezza, Silvia Stacchiotti, Frederic Chibon, Jean-Michelle Coindre, Antoine Italiano, Cleofe Romagnosa, Silvia Bague, Angelo Paolo Dei Tos, Luca Braglia, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Antonella Brunello, Jean-Yves Blay, Robert Diaz Beveridge, Iwona Lugowska, Tom Lesluyes, Roberta Maestro, Franco Domenico Merlo, Paolo Giovanni Casali, Alessandro Gronchi
Summary: The results of this study suggest that CINSARC has weak prognostic power in high-risk, localized soft tissue sarcoma patients.
Review
Oncology
Vincenzo Nasca, Anna Maria Frezza, Carlo Morosi, Ciriaco Buonomenna, Antonina Parafioriti, Giorgio Zappala, Federica Bini, Paolo Giovanni Casali, Mattia Loppini, Silvia Stacchiotti
Summary: Giant cell tumor of the bone (GCTB) is a locally aggressive tumor that can be cured by surgery. For unresectable GCTB, denosumab is currently the only available treatment option. However, long-term use of denosumab may lead to severe side effects such as atypical fracture of the femur. The optimal management of treatment-related atypical fractures is still debated, and it is unknown whether reintroduction of denosumab is feasible at disease progression.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
A. Smrke, A. M. Frezza, C. Giani, N. Somaiah, M. Brahmi, A. M. Czarnecka, P. Rutkowski, W. Van der Graaf, G. G. Baldi, E. Connolly, F. Duffaud, P. H. Huang, H. Gelderblom, V Bhadri, P. Grimison, A. Mahar, S. Stacchiotti, R. L. Jones
Summary: This retrospective study examined the outcomes of patients with advanced clear cell sarcoma (CCS) who received systemic therapy. The results showed that systemic therapies for soft tissue sarcomas had limited benefits and poor response rates in advanced CCS. International, multicentre translational studies are needed to identify new treatments for this rare subtype.
Review
Oncology
Silvia Stacchiotti, Anna Maria Frezza, George D. Demetri, Jean-Yves Blay, Jyoti Bajpai, Giacomo G. Baldi, Elizabeth H. Baldini, Robert S. Benjamin, Sylvie Bonvalot, Judith V. M. G. Bovee, Dario Callegaro, Paolo G. Casali, Sandra P. D'Angelo, Elizabeth J. Davis, Angelo P. Dei Tos, Elizabeth G. Demicco, Jayesh Desai, Palma Dileo, Mikael Eriksson, Hans Gelderblom, Suzanne George, Rebecca A. Gladdy, Mrinal M. Gounder, Abha A. Gupta, Rick Haas, Andrea Hayes, Peter Hohenberger, Kevin B. Jones, Robin L. Jones, Bernd Kasper, Akira Kawai, David G. Kirsch, Eugenie S. Kleinerman, Axel Le Cesne, Roberta Maestro, Javier Martin Broto, Robert G. Maki, Aisha B. Miah, Emanuela Palmerini, Shreaskumar R. Patel, Chandrajit P. Raut, Albiruni R. A. Razak, Damon R. Reed, Piotr Rutkowski, Roberta G. Sanfilippo, Marta Sbaraglia, Inga-Marie Schaefer, Dirk C. Strauss, Sandra J. Strauss, William D. Tap, David M. Thomas, Annalisa Trama, Jonathan C. Trent, Winette T. A. van der Graaf, Winan J. van Houdt, Margaret von Mehren, Breelyn A. Wilky, Christopher D. M. Fletcher, Alessandro Gronchi, Rosalba Miceli, Andrew J. Wagner
Summary: This article discusses the minimum requirements for conducting retrospective observational studies (ROS) in ultra-rare sarcomas (URS) to improve their quality and effectiveness. An expert panel reached a consensus on a set of recommendations through a survey and discussion, covering the use of ROS results, selection of participating centers, diagnosis and assessment methods, consistency of data monitoring policies, and more.
CANCER TREATMENT REVIEWS
(2022)
Article
Oncology
Bruno Vincenzi, Andrea Napolitano, Alessandro Comandone, Roberta Sanfilippo, Simone Celant, Pier P. Olimpieri, Susanna Di Segni, Pierluigi Russo, Paolo G. Casali
Summary: This study analyzed the use of trabectedin in Italian patients with soft-tissue sarcomas and found that trabectedin is effective in treating leiomyosarcoma and liposarcoma patients.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Correction
Oncology
J. Y. Blay, N. Hindi, J. Bollard, S. Aguiar Jr, M. Angel, B. Araya, R. Badilla, D. Bernabeu, F. Campos, C. H. S. Caro-Sanchez, B. Carvajal, A. Carvajal Montoya, S. Casavilca-Zambrano, V. Castro-Oliden, M. Chacon, M. Clara, P. Collini, R. Correa Genoroso, F. D. Costa, M. Cuellar, A. P. dei Tos, H. R. Dominguez Malagon, D. Donati, A. Dufresne, M. Eriksson, M. Farias-Loza, P. Fernandez, A. M. Frezza, T. Frisoni, D. Y. Garcia-Ortega, H. Gelderblom, F. Gouin, M. C. Gómez-Mateo, A. Gronchi, J. Haro, L. Huanca, N. Jimenez, M. Karanian, B. Kasper, B. B. Lopes David, A. Lopez-Pousa, G. Lutter, H. Martinez-Said, J. Martinez-Tlahuel, C. A. Mello, J. M. Morales Perez, S. Moura David, A. G. Nascimento, E. J. Ortiz-Cruz, E. Palmerini, S. Patel, Y. Pfluger, S. Provenzano, A. Righi, A. Rodriguez, R. Salas, T. T. G. Santos, K. Scotlandi, T. Soule, S. Stacchiotti, C. Valverde, F. Waisberg, E. Zamora Estrada, J. Martin-Broto
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Paola Bordi, Giuseppe Tonini, Bruno Vincenzi, Marco Tucci, Alessandro Russo, Francesco Pantano, Marco Russano, Luigia Stefania Stucci, Maria Chiara Sergi, Martina Falconi, Maria Antonietta Zarzana, Daniele Santini, Francesco Spagnolo, Enrica T. Tanda, Francesca Rastelli, Francesca Chiara Giorgi, Federica Pergolesi, Raffaele Giusti, Marco Filetti, Francesca Lo Bianco, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel L. Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo A. Ascierto, Corrado Ficorella, David J. Pinato
Summary: The impact of type 2 diabetes mellitus (T2DM) on the clinical outcome of immune checkpoint inhibitors (ICI) in solid tumor patients is uncertain. Patients on glucose-lowering medications (GLM) for T2DM had worse overall survival (OS) and progression-free survival (PFS) independent of the number of GLM received. Among the GLM, metformin use was associated with increased risk of death and disease progression/death. Further studies are needed to understand the relative impact of metformin and preexisting T2DM diagnosis on outcomes in this population.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Claudia Giani, Stefano Radaelli, Rosalba Miceli, Lorenza Gandola, Claudia Sangalli, Anna Maria Frezza, Salvatore Provenzano, Sandro Pasquali, Rossella Bertulli, Marco Fiore, Dario Callegaro, Michela Casanova, Stefano Chiaravalli, Paola Collini, Gian Paolo Dagrada, Carlo Morosi, Nadia Zaffaroni, Paolo G. Casali, Andrea Ferrari, Alessandro Gronchi, Silvia Stacchiotti
Summary: A retrospective study on primary DSRCT was conducted to characterize long-term survivors (LTS). It was found that 13% of patients achieved cure, who had no liver or extra-abdominal metastasis at diagnosis, received complete surgery, and possibly underwent whole abdomino-pelvic radiotherapy (WAP-RT) and maintenance chemotherapy (MC).
Article
Oncology
Maurizio Muscaritoli, Alessandra Modena, Matteo Valerio, Paolo Marchetti, Roberto Magarotto, Silvia Quadrini, Filomena Narducci, Giuseppe Tonini, Teresa Grassani, Luigi Cavanna, Camilla Di Nunzio, Chiara Citterio, Marcella Occelli, Antonia Strippoli, Bruno Chiurazzi, Antonio Frassoldati, Giuseppe Altavilla, Antonio Lucenti, Fabrizio Nicolis, Stefania Gori
Summary: Malnutrition and cachexia in cancer patients have a negative impact on treatment, outcomes, quality of life, and survival. However, the risk of malnutrition and cachexia is still overlooked in cancer patients. A study revealed that 51% of patients already had nutritional deficiencies at their first oncology visit. These findings emphasize the importance of proactive, early management of malnutrition in cancer patients.